| Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin R Garzon, M Garofalo, MP Martelli, R Briesewitz, L Wang, ... Proceedings of the National Academy of Sciences 105 (10), 3945-3950, 2008 | 628 | 2008 |
| Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein F Fazi, S Racanicchi, G Zardo, LM Starnes, M Mancini, L Travaglini, ... Cancer cell 12 (5), 457-466, 2007 | 485 | 2007 |
| Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized … S Amadori, S Suciu, D Selleslag, F Aversa, G Gaidano, M Musso, ... Journal of Clinical Oncology 34 (9), 972-979, 2016 | 365 | 2016 |
| Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia FF Ferrara, F Fazi, A Bianchini, F Padula, V Gelmetti, S Minucci, ... Cancer research 61 (1), 2-7, 2001 | 338 | 2001 |
| A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol M Mancini, D Scappaticci, G Cimino, M Nanni, V Derme, L Elia, A Tafuri, ... Blood 105 (9), 3434-3441, 2005 | 253 | 2005 |
| A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlyingPLZF/RARA gene rearrangements D Sainty, V Liso, A Cantù-Rajnoldi, D Head, MJ Mozziconacci, C Arnoulet, ... Blood, The Journal of the American Society of Hematology 96 (4), 1287-1296, 2000 | 244 | 2000 |
| Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration G Alimena, E Morra, M Lazzarino, AM Liberati, E Montefusco, D Inverardi, ... | 238 | 1988 |
| AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features C Haferlach, C Mecucci, S Schnittger, A Kohlmann, M Mancini, A Cuneo, ... Blood, The Journal of the American Society of Hematology 114 (14), 3024-3032, 2009 | 225 | 2009 |
| Consumer behaviour through the eyes of neurophysiological measures: State-of-the-art and future trends P Cherubino, AC Martinez-Levy, M Caratu, G Cartocci, G Di Flumeri, ... Computational intelligence and neuroscience 2019, 2019 | 198 | 2019 |
| High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial R Willemze, S Suciu, G Meloni, B Labar, JP Marie, CJM Halkes, P Muus, ... Journal of clinical oncology 32 (3), 219-228, 2014 | 187 | 2014 |
| Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression G Zardo, A Ciolfi, L Vian, LM Starnes, M Billi, S Racanicchi, C Maresca, ... Blood, The Journal of the American Society of Hematology 119 (17), 4034-4046, 2012 | 186 | 2012 |
| Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia G Cimino, F Lo-Coco, S Fenu, L Travaglini, E Finolezzi, M Mancini, ... Cancer research 66 (17), 8903-8911, 2006 | 156 | 2006 |
| Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 … A Vitale, A Guarini, C Ariola, M Mancini, C Mecucci, A Cuneo, F Pane, ... Blood 107 (2), 473-479, 2006 | 156 | 2006 |
| MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia A Tafuri, C Gregorj, MT Petrucci, MR Ricciardi, M Mancini, G Cimino, ... Blood, The Journal of the American Society of Hematology 100 (3), 974-981, 2002 | 150 | 2002 |
| Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem R Latagliata, MC Petti, S Fenu, M Mancini, MAA Spiriti, M Breccia, ... Blood, The Journal of the American Society of Hematology 99 (3), 822-824, 2002 | 148 | 2002 |
| Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis S Luatti, F Castagnetti, G Marzocchi, C Baldazzi, G Gugliotta, I Iacobucci, ... Blood, The Journal of the American Society of Hematology 120 (4), 761-767, 2012 | 145 | 2012 |
| NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia B Falini, C Mecucci, G Saglio, FL Coco, D Diverio, P Brown, F Pane, ... haematologica 93 (3), 439-442, 2008 | 117 | 2008 |
| Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features A Guarini, G Gaidano, FR Mauro, D Capello, F Mancini, MS De Propris, ... Blood 102 (3), 1035-1041, 2003 | 108 | 2003 |
| Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive … F Pane, G Cimino, B Izzo, A Camera, A Vitale, C Quintarelli, M Picardi, ... Leukemia 19 (4), 628-635, 2005 | 105 | 2005 |
| Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA … F Castagnetti, N Testoni, S Luatti, G Marzocchi, M Mancini, S Kerim, ... Journal of clinical oncology 28 (16), 2748-2754, 2010 | 97 | 2010 |
